Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BLTE 
Belite Bio Inc ADR (BLTE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: BLTE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $93.25
1 Year Target Price $93.25
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.2% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.88B USD | Price to earnings Ratio - | 1Y Target Price 93.25 |
Price to earnings Ratio - | 1Y Target Price 93.25 | ||
Volume (30-day avg) 5 | Beta -1.47 | 52 Weeks Range 49.00 - 91.92 | Updated Date 10/18/2025 |
52 Weeks Range 49.00 - 91.92 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -11.68% | Return on Equity (TTM) -17.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2287029752 | Price to Sales(TTM) - |
Enterprise Value 2287029752 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -35.61 | Shares Outstanding 32833402 | Shares Floating 15173343 |
Shares Outstanding 32833402 | Shares Floating 15173343 | ||
Percent Insiders 50.45 | Percent Institutions 0.7 |
Upturn AI SWOT
Belite Bio Inc ADR
Company Overview
History and Background
Belite Bio, Inc. is a biopharmaceutical company that focuses on developing novel therapeutics for inherited retinal diseases with unmet medical needs. Founded with a focus on rare diseases, Belite Bio has advanced its lead candidate, Tinlarebant, through clinical trials.
Core Business Areas
- Drug Development: Focuses on research, development, and commercialization of therapies for retinal degenerative diseases and metabolic diseases. Tinlarebant is their lead drug candidate. The company has licensed IP to develop a treatment to slow the progression of Stargardt disease.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates. Currently focusing on Tinlarebant for Stargardt disease and other indications.
Leadership and Structure
Belite Bio's leadership team includes key executives with expertise in drug development and commercialization. The company operates with a focus on strategic partnerships and collaborations to advance its pipeline.
Top Products and Market Share
Key Offerings
- Tinlarebant: An oral therapy in development for Stargardt disease (STGD1). It's designed to reduce the accumulation of toxic vitamin A dimers (bisretinoids) in the retina. Market share is currently 0% as it is not yet approved, expected to have a high market share if approved. Competitors include companies developing gene therapies and other novel treatments for Stargardt disease, such as Alkeus Pharmaceuticals.
Market Dynamics
Industry Overview
The biopharmaceutical industry for inherited retinal diseases is characterized by high unmet medical needs, increasing R&D investments, and regulatory pathways for rare diseases. Gene therapy and small molecule approaches are rapidly evolving. The current market is estimated to be in the billions and is expected to grow.
Positioning
Belite Bio is positioned as a player developing a novel oral therapy for Stargardt disease. Its competitive advantage lies in potentially offering a more convenient and accessible treatment option compared to gene therapy, which requires invasive procedures.
Total Addressable Market (TAM)
The TAM for Stargardt disease therapeutics is estimated to be significant, considering the prevalence of the condition and the lack of approved treatments. Belite Bio aims to capture a substantial portion of this market with Tinlarebant, contingent upon successful clinical trial outcomes and regulatory approval. TAM is estimated at 5-10 Billion USD
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Oral administration (convenience)
- Focus on unmet medical needs
- Strong patent portfolio
Weaknesses
- Single lead product (Tinlarebant)
- Clinical trial risk
- Dependence on regulatory approval
- Limited commercialization experience
Opportunities
- Expansion to other retinal diseases
- Strategic partnerships
- Fast-track regulatory pathways
- Increased awareness of inherited retinal diseases
Threats
- Competition from gene therapy companies
- Clinical trial failures
- Regulatory setbacks
- Pricing and reimbursement challenges
Competitors and Market Share
Key Competitors
- ALKS
- CRSP
- EDIT
Competitive Landscape
Belite Bio faces competition from established pharmaceutical companies and smaller biotech firms developing treatments for retinal diseases. Competition is intense, but success in Stargardt disease could give Belite Bio a significant advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancing Tinlarebant through clinical trials and securing partnerships.
Future Projections: Future growth depends heavily on the successful completion of ongoing clinical trials and regulatory approval for Tinlarebant. Analyst projections vary widely, reflecting the uncertainty inherent in drug development.
Recent Initiatives: Recent initiatives include continuing clinical trials for Tinlarebant, exploring potential partnerships, and securing funding to support research and development.
Summary
Belite Bio is a high-risk, high-reward biopharmaceutical company focused on developing treatments for inherited retinal diseases. Their lead candidate, Tinlarebant, shows promise but faces clinical trial and regulatory hurdles. Success in Stargardt disease could lead to significant growth, but competition and potential setbacks pose significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. Future projections are subject to change based on market conditions and company performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Belite Bio Inc ADR
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2022-04-29 | Chairman of the Board of Directors & CEO Dr. Yu-Hsin Lin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.belitebio.com |
Full time employees 25 | Website https://www.belitebio.com | ||
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.